



BirchBioMed, Inc. to Present at the 11th Annual LD Micro Main Event

VANCOUVER, BC (November 29, 2018) - BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation, today announced that it will be presenting at the 11th annual LD Micro Main Event on Tuesday, December 4, 2018 at 12:00 p.m. PST / 3:00 p.m. EST. Mark Miller, chief executive officer of BirchBioMed will be presenting and meeting with investors along with Ryan Hartwell, Ph.D, chief science officer.

The presentation will be webcast and may be accessed on the company's website at <http://birchbiomed.ca> or [here](#).

"Internally, our entire year leads up to the Main Event. It has become the 'one thing' everyone in the small and micro-cap world knows us for," stated Chris Lahiji. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the most interesting businesses in the world to our ever-growing community."

The LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel, will feature 250 companies, and will be attended by over 1,200 individuals.

Profiles powered by [LD Micro](#)— News Compliments of [Accesswire](#)

About BirchBioMed

BirchBioMed Inc. is a biomedical company focused on the commercialization, clinical evaluation and development of proprietary anti-scarring drugs, autoimmune therapeutics/therapies and novel strategies for transplantation. As a University of British Columbia (UBC) spinoff, BirchBioMed holds the exclusive, worldwide pharmaceutical license for two medical therapeutic technologies from UBC, which the university considers to be significant medical breakthroughs in the treatment of scarring and certain autoimmune diseases.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

Source: BirchBioMed via LD Micro